Table 1 Patient demographics from TM study.
Total patients | N = 75 |
|---|---|
Median age, y (range) | 51 (29–66) |
Post-menopausal at study entry | 52 (69%) |
AJCC stage | Â |
Stage II, n (%) | 4 (5) |
Stage III, n (%) | 41 (54) |
Stage IV NED, n (%) | 30 (40.0) |
Median tumor size in stage II/III adjuvant pts, cm (range) | 2.3 (1.2–7.0) |
Median positive lymph nodes in stage II/III adjuvant pts, n (range) | 6 (1–42) |
Prior disease sites for stage IV pts, n | Â |
Chest wall | 13 |
Liver | 4 |
Bone only, axilla, lung | 3 each |
Brain | 2 |
Peritoneum | 1 |
Molecular subtype, n (%) | Â |
Luminal A | 7 (9.3) |
Luminal B | 13 (17.3) |
Luminal A/B | 10 (13.33) |
Her2-neu positive | 9 (12.0) |
Triple-negative | 36 (48.0) |
Prior adjuvant antitumor therapy, n (%) | Â |
Anthracycline and taxane-based therapy | 54 (72.0) |
Adriamycin-based therapy | 6 (8.0) |
Cytoxan, Methotrexate, 5-Fluorouracil therapy | 5 (6.7) |
Trastuzumab | 7 (9.3) |
Median number of prior chemo regimens in the metastatic setting, n (range) | 1 (0–3) |
Endocrine therapy on TM, n (%) | Â |
Tamoxifen | 13 (17.3) |
Aromatase inhibitors | 17 (22.7) |
Previous aromatase inhibitors or tamoxifen use | 11 (14.7) |
Leuprolide | 8 (10.7) |
